2 active not recruiting, 2 completed, 2 recruiting. 6 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Active not recruiting 2, Completed 2, Recruiting 2 |
Follow Advanced Colorectal Cancer: new trials by email Literature Review of Advanced Colorectal Cancer trials Research Report on Advanced Colorectal Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study of SHR-A1811 in Combination With Chemotherapy and Bevacizumab Versus Standard Therapy as First-Line Treatment for Advanced Colorectal Cancer SHR-A1811, Oxaliplatin, Levo-leucovorin, Fluorouracil and Bevacizumab, Oxaliplatin, Levo-leucovorin, Fluorouracil and Bevacizumab - Advanced Colorectal Cancer | Phase 3 | Recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 300 | 2026-08-28 | 2026-09-10 |
| Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, and Irinotecan SHR-A1811, TAS-102, Regorafenib , Fruquintinib - Advanced Colorectal Cancer | Phase 3 | Active not recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 130 | 2024-03-01 | 2025-07-17 |
| FOLICOLOR TRIAL: Following Therapy Response Through Liquid Biopsy in Metatstatic Colorectal Cancer Patients Evaluation therapy through Liquid Biopsy - Advanced Colorectal Cancer | Phase 3 | Recruiting | University Hospital, Antwerp | 150 | 2021-08-16 | 2026-04-30 |
| Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10) MRTX849, Cetuximab, mFOLFOX6 Regimen - Advanced Colorectal Cancer, Metastatic Colorectal Cancer | Phase 3 | Active not recruiting | Mirati Therapeutics Inc. | 461 | 2021-06-24 | 2026-09-28 |
| A Phase 3 Study to Evaluate Xilonix as an Anticancer Therapy in Patients With Symptomatic Colorectal Cancer Xilonix, Placebo - Symptomatic Colorectal Cancer, Advanced Colorectal Cancer | Phase 3 | Completed | Janssen Research & Development, LLC | 276 | 2014-07-31 | 2021-03-01 |
| Sequential Versus Combination Chemotherapy in Advanced Colorectal Carcinoma capecitabine-irinotecan, capecitabine+irinotecan (1st line) - Advanced Colorectal Cancer | Phase 3 | Completed | Dutch Colorectal Cancer Group | 820 | 2003-01-01 | 2008-09-08 |
Colorectal Neoplasms (2) · Colonic Neoplasms (1) · Neoplasms (1) · Rectal Neoplasms (1)
Colonic Diseases (2) · Digestive System Diseases (2) · Digestive System Neoplasms (2) · Gastrointestinal Diseases (2) · Gastrointestinal Neoplasms (2) · Intestinal Diseases (2) · Intestinal Neoplasms (2) · Neoplasms (2) · Neoplasms by Site (2) · Rectal Diseases (2)
Bevacizumab (1) · Cetuximab (1) · Fluorouracil (1) · HMPL-013 (1) · Levoleucovorin (1) · Oxaliplatin (1) · adagrasib (1) · bermekimab (1) · capecitabine-irinotecan combination (1) · regorafenib (1) · trifluridine tipiracil drug combination (1)
Suzhou Suncadia Biopharmaceuticals Co., Ltd. (2) · Dutch Colorectal Cancer Group (1) · Janssen Research & Development, LLC (1) · Mirati Therapeutics Inc. (1) · University Hospital, Antwerp (1)
China (3) · Belgium (2) · Poland (2) · Argentina (1) · Australia (1) · Austria (1) · Brazil (1) · Canada (1) · Colombia (1) · Czechia (1) · Denmark (1) · Finland (1) · France (1) · Germany (1) · Greece (1)
C. J. A. Punt, Prof.Dr. (1) · Timon Vandamme (1)
PMID 16873425, PMID 17630036, PMID 23692811, PMID 28094194, PMID 39752885